ǰÑÔ
¾µäÓÕ·¢ÐÔÅÁ½ðɲ¡¶¯ÎïÄ£×Ó£¬¶à½ÓÄÉÀûѪƽ¡¢6-OHDA¡¢MPTPÓÕµ¼Äö³ÝÀàºÍÁ鳤ÀදÎï·¨¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
1. ÀûѪƽÊÇÒ»ÖÖÉúÎ︴ºÏÎ¿ÉÒÔͨ¹ý¹Ø±ÕÄÒÄÚ²»¿ÉÄæµÄµ¥°·µÄÔËÊ䣬ÏûºÄÖÐÊàºÍÍâÖܵĵ¥°·£¬µ¼Ö¼¡È⽩Ӳ£¬×ËÊÆÍäÇú£¬Ô˶¯¼õÂý»òÎÞÄÜ£¬´Ó¶ø·ºÆðÁËÓëÅÁ½ðɲ¡ÏàËÆµÄÁÙ´²Ö¢×´¡£
2. 6-OHDAºÍDAµÄ½á¹¹ÏàËÆ¡£ÔÚ¶¯Îï»úÌåÄÚ£¬6-OHDA±»×ªËÍÖÁ¶ù²è·Ó°·ÀàÉñ¾Í¨Â·ÎüÊÕϵͳ£¬6-OHDA´úлµ¼ÖÂÖÚ¶àÑõ»¯Ó¦¼¤Õ÷Ïó£¬ÓÉÓÚ×ÔÓÉ»ùµÄÐγÉ×îÖÕʹµÃDAÉñ¾Ôª¿¹¹ýÑõ»¯ÏµÍ³ÆÆËð£¬Ëæ×Å×ÔÓÉ»ù¶ÔÏßÁ£Ì幦ЧµÄËðÉË£¬ÆäĤÎȹÌÐÔºÍDNAÍêÕûÐÔµÄÆÆËð£¬×îÖÕÖÂʹϸ°ûéæÃü¡£ÔÚ×¢Éä6-OHDAµÄ30·ÖÖÓÄÚ¼´¿ÉÊӲ쵽6-OHDA¶ÔDAÉñ¾ÔªÆÈº¦×÷Óã¬×¢Éä14~26Ìì90£¥ÒÔÉÏDAϸ°ûɥʧ¡£½«²î±ð¼ÁÁ¿µÄ6-OHDA¶¨Î»×¢ÉäÓÚ´óÊóµÄºÚÖÊÖÜΧºÍºÚÖÊÎÆ×´Ìåͨ·ÉϾùÄܹ»Ñ¡ÔñÐÔËð»ÙºÚÖÊÄÚDAÉñ¾Ôª£¬¿ÉÄ£Äâ³ö×Ô¾õÐÔÅÁ½ðɲ¡µÄÔʼ²¡ÀíÀú³Ì£¬×îÖÕ±¬·¢ÀàËÆ×Ô¾õÐÔÅÁ½ðɲ¡¡£
3. ºÚÖÊÑ¡ÔñÐÔ¶¾ÎïMPTP£¬×Ô¼º²»¾ßÓÐÉñ¾¶¾ÐÔ£¬µ«¿ÉÒÔ´©Ô½Ñª£ÄÔ¼¹ÒºÆÁÕÏ£¬²¢Ö÷ÒªÔÚÐÇÐνºÖÊϸ°ûºÍ5-HTÄÜÉñ¾ÔªÄڵĵ¥°·Ñõ»¯Ã¸B×÷Óúóת±äΪÓж¾ÐÔµÄ1£¼×»ù£4±½»ùßÁà¤Àë×Ó(MPP+), È»ºóÊͷŵ½Ï¸°ûÍ⣬MPP+²»¿É´©Ô½Ñª£ÄÔ¼¹ÒºÆÁÕÏ£¬¶øÊǾÓÉDAתÔËÌå½øÈëDAÄÜÉñ¾Ä©ÉҺͰûÌå¡£MPP+¶ÔDAϸ°ûµÄÑ¡ÔñÐÔ¶¾ÐÔÔ´ÓÚËü±»Ñ¡Ôñ ÐÔÉã×ÅÃÔ¾Ôª£¬Ò»µ©½øÈëDAÉñ¾ÔªÄ©ÉÒ£¬MPP+±»ÄæÐÐתÔËÖÁºÚÖÊ£¬´Ó¶øÍ¨¹ý¸ÉÔ¤ÏßÁ£Ì壬ÒýÆðÖ¬ÖʹýÑõ»¯£¬Ê¹µÃĤ½á¹¹ÔÓÂÒ£¬Ó°Ïìϸ°û¹¦Ð§£¬×îÖÕµ¼ÖÂÑ¡ÔñÐÔÆÆËðºÚÖÊDAÄÜÉñ¾Ôª£¬µ¼ÖºÚÖÊDAÄÜÉñ¾Ôª´ó×ÚéæÃü£¬ÎÆ×´ÌåÀÒ°±ËáôÇ»¯Ã¸ÑôÐÔÏËά´ó×ÚËðʧ£¬ÎÆ×´ÌåDA¼°Æä´úл²úÆ·3,4-¶þôÇ»ù±½ÒÒËá¡¢¸ßÏã²ÝËáˮƽ¾ùÏÔ׎µµÍ£¬Ò²ÓкÚÖÊÎÆ×´ÌåС½ºÖÊϸ°ûºÍÐÇÐÎϸ°ûµÄÔöÉúºÍÀ¶°ß¡¢ÏÂÇðÄÔµÈÇøµÄËðÉË£¬ÓëÅÁ½ðɲ¡»¼Õߵĸıä»ùÄÚÇéͬ¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
1. Wistar´óÊó£¬ÌåÖØ200~220g,10ÖÜ£¬¸¹Ç»ÄÚ×¢ÉäÒ»¶¨¼ÁÁ¿µÄÀûѪƽºó¿ÉʹÆä·ºÆð¹Ç÷À¼¡½©Ó²¡¢Õð²ü¡¢ÉíÌåÓÞÃÁ¡¢Ô˶¯ïÔ̼°ÆäËûµÄһЩÀàËÆµÄÅÁ½ðɲ¡ÁÙ´²Ö÷ÒªÔ˶¯Ö¢×´¡£
2. 6-OHDAËðÉË´óÊóÅÁ½ðɲ¡Ä£×Ó£¬6-OHDA¶¨ÏòÐÔ×¢Éäͨ³£¶¨Î»Ç§ÖÐÐÄǰÄÔÊø£¬¶ø²»ÊǺÚÖÊÖÂÃÜÇø£¬ÓÉÓÚǰÕß°üÀ¨ÁËËùÓд«³öÓÚºÚÖÊÖÂÃܲãºÍǰ²à¸ÇÇøµÄDAÄÜÉñ¾Êø¡£Òò´Ë£¬Óë×¢ÉäÓÚºÚÖÊÖÂÃÜÇøÏà±È£¬µ±6-OHDA×¢ÉäÔÚÖÐÐÄǰÄÔÊøÊ±£¬DAϸ°ûɥʧ¸ü¶à£¬²¢ÇÒ6-OHDAÔÚÖÐÐÄǰÄÔÊøµ¼ÖÂËðÉ˵IJ¡Àíת±äÓëÊӲ쵽µÄ×Ô¾õÐÔÅÁ½ðɲ¡Óм«Ç¿µÄÏà¹ØÐÔ¡£³£ÓõÄ6-OHDAËðÉ˵ĴóÊóÅÁ½ðɲ¡Ä£×ÓÊÇ6-OHDAµ¥²àËðÉË´óÊóÅÁ½ðɲ¡Ä£×Ó¡£ËüÊÇÓÃ6-OHDAµ¥²à×¢Éä´óÊóÖÐÄÔºÚÖÊÓÕ·¢µÄµ¥²àÖÐÄÔºÚÖÊDAÉñ¾ÔªËð»ÙÄ£×Ó¡£
Á¢Ì嶨Ïò»ÙËðÏêϸÀú³ÌÈçÏ£¬½«¾Öظ´ÐÐΪ¼ì²âÈ·ÈÏÎÞÐýתÐÐΪµÄ´óÊó¾ÙÐÐʵÑé¡£½ÓÄɾàÀë×¢ÉäÁ½µã·¨ÖÆÄ££º¸¹Ç»×¢Éä10£¥Ë®ºÏÂÈÈ©(40mg/kg) ½«´óÊóÂé×íºó£¬Àο¿ÓÚStoeltingÄÔÁ¢Ì嶨ÏòÒÇÉÏ£¨Ê¹Ë«²à¶ú¸Ë¼â¶Ë²åÈëÍâ¶úµÀ£¬¿ÉÌýµ½“ßÇà꣢Éù£¬²¢Ê¹Í·²¿Á½²à¼á³ÖÔÚˮƽλÖã»Ãųݹ´µÍÓÚ¶ú¸ËÆ½Ãæ2.4mm£¬Ê¹Ç°¡¢ºóضˮƽ¸ß¶ÈÏà²î0.4mmÒÔÏ£©¡£Í¨ÀýÏû¶¾ºó£¬ÇпªÍ·Æ¤Ô¼1.0cm£¬°þÀë¹ÇĤ£¬È·¶¨ÓÒ²àºÚÖÊÖÂÃܲ¿ºÍÖÐÄÔ¸¹²à±»¸Ç×ø±ê£¬ÓÃÕë¼â±ê¼Ç¡£ÑÀ¿Æ×êСÐÄ×ê͸¹ǣ¨×¢ÖØÎðËðÉËÓ²ÄÔĤ£©£¬°´È·¶¨×ø±ê½«Î¢µÖ×¢ÉäÆ÷ÅþÁ¬ÓÚ΢×îÍÆ½øÆ÷ÉÏ£¬±ÊÖ±È룬»ºÂý½øÕëµ½Ô¤¶¨Éî¶È£¬ÏòºÚÖÊÖÂÃÜÇøºÍÖÐÄÔ¸¹²à±»¸ÇÇø¸÷×¢Éä6-OHDA 8µg£¨ÈÜÓÚ4µlº¬ÖÊÁ¿·ÖÊýΪ0.2£¥¿¹»µÑªËáµÄÐÄÀíÑÎË®ÖУ©£¬×¢ÉäÉî¶ÈÓ¦ÒÔÕë¿×Ð±ÃæÖеãΪ²ÎÕյ㣬Õë¼âÏòǰ£¬°ü¹Ü6-OHDAÄÜ׼ȷעÈëÔ¤¶¨²¿Î»£¬×¢ÉäËÙÂÊΪ1μl/min£¬ÁôÕë10·ÖÖÓ£¬»ºÂýÍËÕë(1mm/min)¡£ÑÀ¿Æ½ºÁýÕÖ×ê¿×£¬Í¨Àý·ìºÏÉ˿ڣ¬Ò»Á¬¸¹Ç»×¢ÉäÇàÃ¹ËØ5ÍòUÒ»ÖÜÒÔ±ÜÃâѬȾ¡£
3. ´óÊó¶ÔMPTP²»Ãô¸Ð£¬²»Ò×ÓÕ·¢ÓëÅÁ½ðɲ¡ÁÙ´²ÏàËÆµÄ¶¯ÎïÄ£×Ó£¬ËäȻСÊóÏà¶ÔÃô¸Ð£¬µ«ÔÚ30mg/(kg·d)¼ÁÁ¿5~10ÌìµÄ×÷ÓÃÏ£¬ºÚÖÊA10Çø¡¢À¶°ß¡¢±³ºË¼°ÏÂÇðÄÔµÄÉñ¾ÔªÈÔ²»ÊÜÈκÎÓ°Ïì¡£ÖÆ×÷MPTP·ÇÈËÁ鳤ÀàÅÁ½ðɲ¡Ä£×Ó³£½ÓÄÉ·ÇÈËÁ鳤ÀදÎïÈ«Éí¾²Âö¡¢Ç³¾²Âö¡¢¾±×ܾ²Âö»ò¸¹Ç»×¢ÉäMPTPÒªÁì¾ÙÐС£Ñ¡ÓóÉÄê·ÇÈËÁ鳤ÀදÎעÉäMPTP (0.2~0.5mg/kg)£¬ÌìÌì1´Î£¬¹²15~18Ì죬ҲÓб¨µÀ½öÓÃ4~6Ì죨¼ÁÁ¿¾Þϸ²î±ð¡¢ÄêËêÑ¡Ôñ²î±ð¡¢×¢É䲿λºÍ;¾¶²î±ðÔì³ÉµÄ²î±ð£©£¬ËùÓж¯Îï¾ùÄÜ·ºÆðÅÁ½ðɲ¡ÑùÖ¢×´£¬ÓëÈËÌ屬·¢µÄÖ¢×´ÏàËÆ¡£
¡¾Ä£×ÓÌØµã¡¿£º
1. ÔËÓÃÀûѪƽÓÕ·¢µÄ´óÊóÅÁ½ðɲ¡Ä£×Ó¶Ô¿ìËÙÆÀ¼ÛÖÎÁÆÅÁ½ðɲ¡µÄÒ©Îï¾ßÓÐÖ÷ÒªµÄ¼ÛÖµ¡£¸ÃÄ£×ÓѸËÙÒ׵㬵«ÆäÖ¢×´»á±¬·¢¿ÉÄæÐÔת±ä£¬¸ÃÄ£×ÓµÄÈõµãÊDz»¿ÉÉîÈë¸´ÖÆ×Ô¾õÐÔÅÁ½ðɲ¡µÄ²¡ÀíÀú³Ì¡£Òò´Ë£¬²»¿ÉÓÃÓÚÂýÐÔDAÏûºÄʱ±¬·¢µÄһЩÁÙÊõת±äµÄÑо¿¡£¸ÃÄ£×ÓµÄÁíһȱÏÝÔÚÓÚ£¬ËüÓë×Ô¾õÐÔÅÁ½ðɲ¡Ïà±È£¬µ±5-HT¡¢È¥¼×ÉöÉÏÏÙËØ½µµ½Ò»¸öºÜµÍµÄˮƽʱ£¬¿ÉÄܵ¼ÖÂÁ½Õß±¬·¢²î±ðµÄÒ©Àíѧ·´Ó¦¡£ÁíÍ⣬ͨ¹ý×¢ÉäÀÒ°±ËáÀàËÆÎ1£¼×»ùÀÒ°±Ëᣩ£¬¿ÉÒÖÖÆDAºÍÈ¥¼×ÉöÉÏÏÙËØµÄºÏ³É£¬¶ÔÄö³ÝÀදÎï¾ßÓÐÓëÀûѪƽÓÕµ¼ÏàËÆµÄ¹¦Ð§£¬Òò´Ë¿ÉÑ¡Ôñ´ËÒªÁì¸´ÖÆÅÁ½ðɲ¡Ä£×Ó¡£
2. ÓÉÓÚͬ²àÎÆ×´ÌåDA¹¦Ð§µÄËðʧ£¬¶¯ÎïÌåÏÖ³öÏòÓë6-OHDAÒýÆðµÄËðÉ˲¿Î»Ïà·´²à×Ô¾õÐýת£¬ÌåÏÖÉñ¾½ÚÏòÇðÄÔºÍÖÐÄÔÔ˶¯Çø·¢³öµÄ¼¤¶¯ïÔÌ£¬¸ÃÄ£×Ó¹ØÓÚÏàʶºÚÖÊÎÆ×´Ìåͨ·½µ½âʱ²¡Àí¡¢µçÐÄÀíºÍÒ©Àíѧת±äºÜÊÇÓÐÓã¬ÓÐÀûÓÚÎÒÃǶÔÅÁ½ðɲ¡Ö¢×´±¬·¢ÆøÖƵÄÃ÷È·¡£¼ÙÉèÔÚÅÁ½ðɲ¡ÖÐÕâÖÖ¼¤¶¯ÊôÓÚ¹ýÁ¿Ô˶¯£¬ÄÇôÕâÖÖÐÐΪËù´ú±í×ŵľÍÊÇ¿¹ÅÁ½ðɲ¡µÄ×÷Óá£Ö»¹Ü6-OHDAµ¥²àËðÉ˸´ÖƵĴóÊóÅÁ½ðɲ¡Ä£×ÓÓëÅÁ½ðɲ¡»¼ÕßÔÚ²¡Àíѧ¡¢Ò©ÀíѧµÄת±äÏàËÆ£¬¿ÉÊÇÕâÖÖ¶¯ÎïÄ£×ÓÈÔ±£´æÒ»Ð©Èõµã¡£ÓÉÓÚÔÚÕâ¸öÄ£×ÓÖÐ6-OHDAµÄËðÉËÊôµ¥²à£¬Í¨¹ý´óÄÔ·ÇËðÉ˲àÅâ³¥½éµ¼µÄͨ·£¬¿ÉÒÔÓ°Ïì´óÄԵĵ¥²à×÷ÓÃDAÏûºÄµÄ¸Ä±ä¡£6-OHDAÖÆ±¸µÄ´óÊóÄ£×ÓÐèÒªÁ¢Ì嶨ÏòÒǵÈÌØÊâ×°±¸£¬ÖÆ×÷ÊÖÒÕÒªÇó¸ß£¬µ«´óÊóÒ׿ØÖÆ£¬ÈªÔ´¹ã£¬¼ÛÇ®µÍ£¬ÐÐΪһÁ¬Ê±¼ä³¤ÇÒÊÓ²ìÀû±ã£¬Òò¶øÊdz£ÓõÄÄ£×ÓÖ®Ò»¡£
3. MPTPÓÕµ¼µÄÄö³ÝÀදÎïÄ£×ÓËùÌåÏÖµÄÖ¢×´ºÍ²¡Àíת±äÓëÈËÅÁ½ðɲ¡ÁÙ´²Ö÷ÒªÌåÕ÷ÏàÈ¥ÉõÔ¶¡£ÏÖÔÚ¿´À´Ã»ÓÐÌ«´óµÄÍÆ¹ã¼ÛÖµ¡£MPTPÖÆ±¸µÄ·ÇÈËÁ鳤ÀàÅÁ½ðɲ¡Ä£×ÓÒªÁì¼òÆÓ£¬ÐÐΪÌåÕ÷¡¢²¡ÀíÌØÕ÷ÓëÈËÀà¸üÏàËÆ£¬¼ÓÖ®·ÇÈËÁ鳤Àà½ø»¯ÉϵÄÀàÈËÐÔ¡¢ÊÓ²ìºÍÈ¡²ÄµÄÒײÙ×÷ÐÔ£¬¶øÆÕ±éÊܵ½ÈËÃǵĽӴý¡£´ËÄ£×ÓÏÔ×ÅÓÅÓÚ6-OHDAÄ£×Ó£¬ÊÇÏÖÔÚÓ¦ÓÃ×îÆÕ±éµÄÄ£×Ó¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
1. Ó¦ÓÃÀûѪƽģ×ÓѸËÙ·¢Ã÷ÁËL-DOPA¿É×÷ΪÖÎÁÆÅÁ½ðɲ¡µÄDZÔÚÒ©Îï¡£µ½ÏÖÔÚΪֹ£¬ÕâÖÖÒ©ÎïÒÀÈ»ÊÇÁÙ´²ÖÎÁÆÅÁ½ðɲ¡µÄÊ×ѡҩÎïºÍÖ÷ÒªÒ©Îï¡£
2. 6-OHDAµ¥²àËðÉ˸´ÖƵĴóÊóÅÁ½ðɲ¡Ä£×Ó£¬¿É´ÓÄ£×Ó¶¯ÎïÐýתÊýÄ¿ºÍÆ«ÏòÉϼÓÒÔÆÀ¹À¡£ÓÉÓÚ¶¯ÎïÐÐÎªÌØÒìÐÔ²î±ð£¬ÅжϴóÊóÅÁ½ðɲ¡Ä£×ÓÊÇ·ñÀֳɣ¬Í¨³£ÒÔ¶¯Îï·ºÆðÐýתÐÐΪµÄ´ÎÊýΪ±ê×¼£¬Ò»Ñùƽ³£Áè¼Ý7ת£¯min¼´ÎªÀֳɵÄÅÁ½ðɲ¡Ä£×Ó£¬²»È»Îª²»ÀÖ³ÉÄ£×Ó¡£6-OHDAËðÉ˶¯ÎïÒýÆðµÄÐýת±»ÒÔΪÊÇ¿¹ÅÁ½ðɲ¡µÄÐÐΪ£¬µ«ÖîÈçÕð²ü¡¢Ç¿Ö±ºÍÔ˶¯¼õÂýµÈÅÁ½ðɲ¡µÄÖ÷ÒªÁÙ´²Ö¢×´È´Ã»ÔÚÕâЩ¶¯ÎïÖзºÆð¡£Í¨¹ýË«²à×¢Éä6-OHDAÔÚÄö³ÝÀදÎïÖÐÐÄǰÄÔÊøÒýÆðËðÉ˵IJ½·¥Ò²¿ÉÓÕµ¼³öÅÁ½ðÉ ²¡Ö¢×´£¬¿ÉÊÇһЩµ¹Ô˵ÄÖ¢×´°üÀ¨ÍÌÑÊÄÑÌâ¡¢¸ßÖÂËÀÂʵÈʹµÃÕâЩÅÁ½ðɲ¡Ä£×ÓÎÞ·¨ÆÕ±éÓ¦Óã¬Òò¶ø²»³£Óᣵ±Ö±½ÓÏòÎÆ×´Ìå×¢Éä6-OHDAʱ£¬Ò»Ð©¶¯ÎïÎÆ×´ÌåDAÖÐÊà¶Ëͨ·±¬·¢²¿·ÖºÄ½ß£¬ÔÚÕâÖÖÅÁ½ðɲ¡Ä£×ÓÖУ¬ÎÆ×´ÌåÉñ¾ÔªÍË»¯ËÙÂʷdz£»ºÂý¡£ÓëÖÐÐÄǰÄÔÊø×¢Éä6-OHDAÏà±È£¬ÏòÎÆ×´Ìå×¢Éä6-OHDAʱ£¬ºÚÖÊÎÆ×´ÌåÉñ¾ÔªÍË»¯µÄËÙÂÊÓë×Ô¾õÐÔÅÁ½ðɲ¡¼«ÆäÏàËÆ¡£¿ÉÊÇ£¬¾ÎÆ×´Ìå×¢Éä6-OHDAÒýÆð²¿·ÖËðÉË£¬ÎÆ×´ÌåÖÐDAºÄ½ßȱ·¦¿ÉÒÔÒýÆðÒì³£Ô˶¯¡£Òò´Ë£¬µ±ÆÀ¹ÀÖÎÁÆÅÁ½ðɲ¡ÄÜÁ¦Ê±£¬²»¿ÉʹÓÃÏòÎÆ×´Ìå×¢Éä6-OHDA¸´ÖƵÄÅÁ½ðɲ¡¶¯ÎïÄ£×Ó¡£
3. ·ÇÈËÁ鳤ÀදÎïÊÇÈËÀà½ø»¯Àú³ÌµÄ½üÇ×£¬ÔÚÉñ¾ÏµÍ³µÄ±¬·¢·¢ÓýѧÉÏÌåÏÖ³öÓëÈËÀàÇ×½üµÄÏà¹ØºÍÏàËÆÐÔ£¬ÇÒÆäÐÐΪÓëÈËÀàÐÐΪµÄ¿É±ÈÐÔ£¬¶¼ÌáÐÑ×ÅÑо¿Õß¶ÔËüÃǵĹØ×¢¡£MPTPÒâÍâ·¢Ã÷ºÍÔÚ·ÇÈËÁ鳤ÀදÎïÌåµÄʹÓã¬Ê¹ÅÁ½ðɲ¡¶¯ÎïÄ£×ӵĸ÷·½ÃæÑо¿ÓÐÁ˳¤×ãµÄǰ½ø¡£MPTPËðÉ˺󣬷ÇÈËÁ鳤ÀදÎï»áÏÔʾ×ËÊÆÒì³£¡¢Ô˶¯ïÔÌ¡¢ËÄÖ«Ö÷ÒªÍäÇú¡¢Ö«Ìåǿֱ°éÓÐÕð²ü¡¢ÍÌÑÊÄÑÌâ¡¢²»¿É½øÊ³¡¢·¢ÒôÏ÷Èõ¡¢¶¨Ïò·´Ó¦ÐÔÏ÷ÈõµÈÌåÕ÷¡£¶¯Îï·´Ó¦µÄˮƽÓëMPTP¼ÁÁ¿¼°¶¯ÎïÄêËêÓйأ¬¸øÓèL-DOPAºóËùÓÐÖ¢×´¼õÇá¡£
Ç°ÃæÌá¼°µÄ¶Ô·ÅÏß¾úËØµÈÒ»Ààϸ¾ú¡¢Õæ¾úºÍÖ²Îï¿ÉºÏ³É±¬·¢µÄÂѰ×ÖʽͽâÒÖÖÆ¼ÁÔÚ´óÊóµÄÑо¿Ð§¹û£¬Í¬ÑùÔÚ·ÇÈËÁ鳤ÀàÅÁ½ðɲ¡Ä£×ÓµÄÑÐÖÆÖÐÒýÆð¹Ø×¢¡£ÃÀ¹úMachel Jackson Foundation¡¢Ó¢¹úMotac Neuroscience¡¢·¨¹úBasal GangµÈ¿ç¹úÑо¿»ú¹¹ºÍ×éÖ¯¾ùÒÑÔÚÕâ·½ÃæµÄÑо¿ÖÐÓÐËùͶÈ롣ʹPSIµ¼Ö·ÇÈËÁ鳤ÀàÅÁ½ðɲ¡µÄÑо¿³ÉΪ¸Ã²¡·ÇÈËÁ鳤ÀදÎïÄ£×ÓÖÆ×÷µÄÐÂÈÈÃÅ»°Ìâ¡£ÀîÇØµÈºÍMotac Neuroscience¿ªÕ¹ÏàÖúÑо¿£¬ÒѾ×îÏȲ¢ÇÒ½×¶ÎÐÔµØÍê³ÉÁ˲¿·ÖÑо¿ÊÂÇ飬Ñо¿·¢Ã÷¸ÃÒªÁìÖÆÔìµÄ·ÇÈËÁ鳤ÀàÅÁ½ðɲ¡Ä£×Ó¾ßÓнϸßÓÅÔ½ÐÔ£º¢ÙÔìÄ£ÖÆ¼Á¶¾ÐÔÎÂ˳£¬Ã»ÓÐÆÕ±éµÄ¼±ÐÔ¶¾¸±×÷Ó㬲»»áÒýÆð¶¯Îï̱»¾ºÍéæÃü£¬´ó´ó½µµÍÔìģΣº¦£»¢ÚÔìÄ£Àú³ÌÏà¶Ô»ººÍ£¬ÔÚ¶¯Îï»úÌå²»·ºÆðÇ¿ÁÒÌåÕ÷²¨¶¯µÄÇéÐÎÏ£¬¼´¿ÉÍê³ÉÄ£×ÓµÄÖÆ×÷£¬Ô½·¢½üËÆÓÚÈËÀàÔ·¢ÐÔÅÁ½ðɲ¡µÄ²¡ÀíÀú³Ì£»¢ÛÔÚÄÔÄÚÐγɵIJ¡±ä»»ÀàËÆÓÚÈËÀ࣬ÓÈÆäÊǺÚÖÊÖÐDAÉñ¾ÔªµÄȱʧµÄPETÄ¥Á·Ô½·¢Äܹ»Åú×¢ÆäÄ£×ÓÏàËÆÐÔ£»¢Ü¶¯ÎïÄ£×ÓµÄÐÐΪÌåÏÖÓëMPTPËðÉËÎȹ̺óµÄÄ£×ÓÎÞÏÔ×Ųî±ð¡£¹ØÓÚÔÚºÚÖÊDAÉñ¾ÔªÖÐÊÇ·ñ¿É¼ûLewyÑùÈÝÄÉÌ壬»¹Òª½øÒ»²½ÊӲ졣
×ÛÉÏËùÊö£¬ÓÉÓÚÅÁ½ðɲ¡·¢²¡»úÖÆ²¢²»ÊǺÜÃ÷È·£¬ÏÖÓÐÄ£×ÓºÍ×Ô¾õÅÁ½ðɲ¡²»¾ßÓÐÍêÈ«Ïàͬ²¡Òòѧ£¬µ«Ò»¶¨ÓÐÏàËÆÐÔ¡£ÒÑÓеļ¸ÖÖ·ÇÈËÁ鳤ÀàºÍÄö³ÝÀදÎïÄ£×Ó¶¼ÊÇͨ¹ý¶ÔÄÔ²¿Ê©¼ÓʵÑéÒòËØÍê³ÉµÄ£¬ÕâЩģ×Ó¶¼²»»á·ºÆðÓëÔ·¢ÐÔÅÁ½ðɲ¡ÍêÈ«ÏàͬµÄ²¡ÀíÐÄÀí¸Ä±äºÍÉñ¾·Ö½âģʽ£¬ÌØÊâÊÇÔÚ¼²²¡¾ÙÐÐÐÔת±ä·½Ãæ¸ü²»¿ÉºÜºÃÌåÏÖ¡£ÔÚÏÖÔÚ»¹Ã»ÓиüºÃµÄÔìÄ£ÒªÁìµÄÇéÐÎÏ£¬¿ÉÒÔ˵£¬MPTPÓÕµ¼µÄ·ÇÈËÁ鳤ÀàÅÁ½ðɲ¡Ä£×ÓÊÇÏÖÔÚ½ÏΪ³ÉÊì¡¢ÓмÛÖµµÄÅÁ½ðɲ¡Ñо¿ÔØÌ壬MPTPÖÆ±¸µÄ·ÇÈËÁ鳤ÀàÅÁ½ðɲ¡Ä£×Ó£¬ÒªÁìÇáÓ¯£¬ÐÐΪºÍ²¡Àí·½ÃæµÄת±äÓëÈËÏà½ü¡£PSIÓÕµ¼µÄ·ÇÈËÁ鳤ÀàŽðɲ¡Ä£×Ó²»µ«º¸ÇÁËMPTPÖÆ±¸µÄ·ÇÈËÁ鳤ÀàÅÁ½ðɲ¡Ä£×ÓµÄËùÓÐÓŵ㣬²¢ÇÒÔÚ¼²²¡±¬·¢ÉÏÔ½·¢ÓëÈËÀàÔ·¢ÐÔÅÁ½ðɲ¡ÏàËÆ£¬ÊÇÇéÐζ¾ËØÖ²¡Ñ§ËµµÄÓÐÁ¦×ôÖ¤£¬ÓÐÁÉÀ«¿ª·¢ºÍÓ¦ÓÃÔ¶¾°¡£
ÀàËÆÓÚÈ˵ÄÅÁ½ðɲ¡ÁÙ´²¼Ì·¢Ö¢£¬Ê¹ÓÃMPTPÓÕµ¼â¨ºï·ºÆðÅÁ½ðɲ¡Ö÷ÒªÌåÕ÷Ö®ºó£¬»úÌåÒ²»á·ºÆðÐí¶à²¡Àí¡¢ÐÄÀí¡¢´úл¹¦Ð§ÉϵÄת±ä£¬ÕâЩ×ÛºÏÒòËØÅäÏàÖúÓõÄЧ¹û¾Í»áʹ¶¯Îï·ºÆðÖÖÖÖ¸÷ÑùµÄÁÙ´²Ö¢×´¡£Ëæ×ÅÅÁ½ðɲ¡Èý´óÖ÷ÒªÌåÕ÷£ºÔ˶¯¼õÂý¡¢Õð²üºÍǿֱµÄ·ºÆðºÍ¼Ó¾ç£¬¶¯ÎïµÄʳÓûºÍ²ÉʳÄÜÁ¦Ò²Ò»Ö±Ï½µ£¬Èô²»ÊµÊ±½ÓÄÉÏìÓ¦µÄ¶Ô²ßºÍÓÐÓõĴ¦Öóͷ£ÒªÁ죬¶¯ÎïµÄÌåÖʽ«Ñ¸ËÙ½µµÍ£¬·ºÆðÏû»¯²»Á¼¡¢±ãÃØ¡¢ÏûÊÝ¡¢¼¡ÈâήËõµÈÓëÓªÑøÓÐ¹ØµÄÆäËûÌåÕ÷£¬½øÒ»²½Éú³¤£¬¶¯ÎïµÄÃâÒß¹¦Ð§Ò²Öð½¥µÍÏ£¬Ìõ¼þÖ²¡²¡ÔÌåÑ¬È¾ËæÖ®·ºÆð¡£ÕâÔÚÒÑ´¦ÓÚÅÁ½ðɲ¡Ö÷ÒªÌåÕ÷״̬ÏµĶ¯Îï¾ÍºÜÓпÉÄÜÎÞ·¨ÔâÊÜ£¬Ö¶¯Îï¾ÈÖÎÎÞЧÓÚ³ÉÄ£ÖÐ;éæÃü£¬ÊµÑéʧ°Ü¡£Òò´Ë£¬Ò»Ì×ÓÐÓõļ̷¢Ö¢·ÀÖμƻ®ºÍÒ»¸öÓÅÒìµÄ¡¢È«¼ÛµÄ¡¢Ò×ÓÚÅÁ½ðɲ¡Ì¬Ï¶¯ÎïÏû»¯ÎüÊÕµÄÓªÑøÊ³ÎïÅä·½¶Ô°ü¹Ü´óÅúÁ¿ÔìÄ£ÊÂÇéµÄ˳Ëì¾ÙÐÐÊǺÜÊÇÖ÷ÒªµÄ¡£Ðí¶àÑо¿Ö°Ô±ÔÚÔìÄ£Àú³ÌÖлáÓöµ½´ËÀàÎÊÌ⣬ÐèҪ͎áÆäÏêϸÇéÐζÔÅÁ½ðɲ¡Ä£×Ó¶¯Îï¿ÉÄÜ·ºÆðµÄÖݪֲ¢·¢Ö¢ÓÐÕë¶ÔÐÔ¾ÙÐÐÔ¤·ÀºÍ´¦Öóͷ££¬ÒÔ°ü¹ÜÄ£×Ó¶¯ÎïµÄºã¾Ãά³Ö¡£
²Î¿¼ÎÄÏ×£º
1.³ÂÉúµÜ£®ÅÁ½ðɲ¡£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉ磬2006
2.Engeln M, Ahmed SH, Vouillac C, el al. Reinforcing properties of Praroipexole in normal and parkinsooian rats.Neurobiol Dis, 2012, 49C: 79-86
3.Hoehn MM, Yahr MD. Parkinsonism:onset, progression and mortality. 1967. Neurology,2001,57(10 Suppl 3): S11-26
4.KitamuraY,Shimohama S,Akaike A,et al.The parkinsonian models: invertebrates to mammals. Jpn J Phannacol, 2000, 84 (3):237-243
5.Luquin MR. Experimental models of Parkinson disease. Rev Neurol, 2000, 31 (1):60-66
6.Marti M,Rodi D,Li Q,et al. Nociceptin/orphanin FQ receploT agonists allenuate L-DOPA-induced dyskinesias. J Neurosci,2012,32(46): 16106-16119
7.Meissner W, Hill MP, Tison F, et al. Neuroprotective strategies for Parkinson's disease: Conceptual limits of animal models and clinical trials. Trends Pharmacol Sci, 2004, 25 (5):249-253
8.Mokry J. Experimental models and behavioural tests used in the study of Parkinson's disease. Physiol Res,1995, 44 (3):143-150
9.Parkinson J. An essay on the shaking palsy. London: herwwod, Nelly and Jones, 1817
10.Tolwani RJ, Jakowec MW, Petzinger GM, et al. Experimental models of Parkinson's disease: insights from many models. Lab Anim Sci, 1999,49 (4):363-371